Targeting mechanisms of cGMP dependent protein kinases by peptide arrays and crys

肽阵列和crys的cGMP依赖性蛋白激酶靶向机制

基本信息

  • 批准号:
    8286410
  • 负责人:
  • 金额:
    $ 30.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): cGMP-dependent protein kinase (PKG) is the central enzyme of NO-cGMP signaling pathway that regulates platelet aggregation, smooth muscle tone, phototransduction, and leukocyte migration [1,2]. Although PKG has been heavily targeted for treating diseases such as, erectile dysfunction and cardiovascular and pulmonary diseases, developing specific activators and inhibitors has been difficult because there is no structural information available[1,2]. For the successful NO-cGMP mediated signaling responses to occur, PKG has to be localized to the specific site in the cell. Localization of PKG is an essential feature of the NO-cGMP signaling and mediated by G Kinase Anchoring Proteins (GKAPs)[3,4,5,6,7,8]. In particular, the variable leucine zipper domain at the extreme N-terminus targets PKG to specific subcellular sites via its interaction with G-kinase anchoring proteins in an isotype specific manner [7,9]. Despite mounting evidence that GKAP target PKGs via its association with the zipper domain, the molecular details of this important protein- protein interaction remain unknown. The specific aims of this proposal are to understand the isotype specific targeting mechanism of PKGs using peptide arrays in combination with X-ray crystallography. Adding another layer of complexity, there are three types of PKG (I1, I2, and II) that each have different cGMP dependence in activation, unique sets of substrates, and tissue specific expression [2,10,11]. My primary focus is the type I isozymes (1 and 2) that have been implicated in erectile dysfunction and many cardiovascular diseases. Although they represent functionally non- redundant proteins with unique physiological roles, their functional roles and specific subcellular localization are poorly understood. In order to elucidate isozyme specific functions and localization, I plan to solve crystal structures of the PKG I1 and 2 zipper domains and compare molecular features of GKAP docking surfaces that are unique to each isoform. In parallel, I plan to engineer peptides that can selectively disrupt interactions between both isozymes of PKG I and their individual binding partners. Lastly, I will incorporate high affinity peptides into the co-crystallization trials in order to understand molecular details of the PKG/GKAP interaction. My plan is to form stable protein/peptide complexes using isozyme specific peptides and pursue high-resolution crystal structures of PKG/GAKP complexes. Solution of the zipper domain structures, and development of small peptides that specifically disrupt isozyme specific targeting, will pave the way to elucidation of the specific functions of PKGs and eventually lead to the development of therapeutic agents. PUBLIC HEALTH RELEVANCE: cGMP-dependent protein kinase (PKG) is the central enzyme of NO-cGMP signaling pathway that regulates platelet aggregation, smooth muscle tone, phototransduction, and leukocyte migration. Although PKG has been heavily targeted for treating diseases such as, erectile dysfunction and cardiovascular and pulmonary diseases, developing specific activators and inhibitors has been difficult because there is no structural information available. My ultimate goal is to rationally target the kinase by obtaining high-resolution crystal structures of PKG and its isozymes and develop pharmacological agents that can modulate the activity of the kinase to treat diseases related to NO-cGMP signaling dysfunction.
描述(由申请人提供):CGMP依赖性蛋白激酶(PKG)是调节血小板聚集,平滑肌张力,光转导和白细胞迁移的NO-CGMP信号通路的中心酶[1,2]。尽管PKG已被严重针对治疗诸如勃起功能障碍以及心血管和肺部疾病之类的疾病,但由于没有可用的结构信息[1,2],因此很难开发特定的激活剂和抑制剂。 为了成功发生的无CGMP介导的信号反应,必须将PKG定位于细胞中的特定位点。 PKG的定位是NO-CGMP信号传导的重要特征,并由G激酶锚定蛋白(GKAP)介导[3,4,5,6,7,8]。特别是,极端N末端的可变亮氨酸拉链结构域通过与G-激酶锚定蛋白的相互作用以同种型特异性方式靶向特定的亚细胞位点[7,9]。尽管有证据表明GKAP靶PKG通过其与拉链结构域的关联,但这种重要的蛋白质蛋白质相互作用的分子细节仍然未知。该提案的具体目的是使用肽阵列与X射线晶体学结合使用PKG的同种型特异性靶向机制。 添加另一层复杂性,有三种类型的PKG(I1,I2和II),每个PKG在激活中具有不同的CGMP依赖性,唯一的底物集和组织特异性表达[2,10,11]。我的主要重点是与勃起功能障碍和许多心血管疾病有关的I类同工酶(1和2)。尽管它们代表具有独特生理作用的功能性冗余蛋白质,但它们的功能作用和特定的亚细胞定位知之甚少。为了阐明同工酶特异性功能和定位,我计划求解PKG I1和2个拉链域的晶体结构,并比较每个同工型独特的GKAP对接表面的分子特征。同时,我计划设计可以选择性破坏PKG I同工酶及其个体结合伴侣之间相互作用的肽。最后,我将将高亲和肽纳入共结晶试验中,以了解PKG/GKAP相互作用的分子细节。我的计划是使用同工酶特异性肽形成稳定的蛋白/肽络合物,并追求PKG/GAKP复合物的高分辨率晶体结构。拉链结构结构的溶液以及特异性破坏同工酶特异性靶向的小肽的开发,将为阐明PKG的特定功能铺平道路,并最终导致治疗剂的发展。 公共卫生相关性:CGMP依赖性蛋白激酶(PKG)是调节血小板聚集,平滑肌张力,光转导和白细胞迁移的NO-CGMP信号通路的中心酶。尽管PKG已被旨在治疗诸如勃起功能障碍以及心血管和肺部疾病之类的疾病,但由于没有可用的结构信息,因此很难开发特定的激活剂和抑制剂。我的最终目标是通过获得PKG及其同工酶的高分辨率晶体结构,并开发可以调节激酶的活性以治疗与NOCMP信号传导功能障碍相关的疾病的药理剂,从而合理地靶向激酶。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Choel Woong Kim其他文献

Choel Woong Kim的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Choel Woong Kim', 18)}}的其他基金

TARGETING CGMP KINASES TO DEVELOP NEW THERAPEUTICS FOR HYPERTENSIVE DISEASES
针对 CGMP 激酶开发高血压疾病新疗法
  • 批准号:
    8384906
  • 财政年份:
    2012
  • 资助金额:
    $ 30.21万
  • 项目类别:
TARGETING CGMP KINASES TO DEVELOP NEW THERAPEUTICS FOR HYPERTENSIVE DISEASES
针对 CGMP 激酶开发高血压疾病新疗法
  • 批准号:
    8512778
  • 财政年份:
    2012
  • 资助金额:
    $ 30.21万
  • 项目类别:
Targeting mechanisms of cGMP dependent protein kinases by peptide arrays and crys
肽阵列和crys的cGMP依赖性蛋白激酶靶向机制
  • 批准号:
    8102997
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:
Activation and Regulation Mechanisms of cGMP-dependent Protein Kinase I and II
cGMP依赖性蛋白激酶I和II的激活和调节机制
  • 批准号:
    8962633
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:
Targeting mechanisms of cGMP dependent protein kinases by peptide arrays and crys
肽阵列和crys的cGMP依赖性蛋白激酶靶向机制
  • 批准号:
    8690098
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:
Targeting mechanisms of cGMP dependent protein kinases by peptide arrays and crys
肽阵列和crys的cGMP依赖性蛋白激酶靶向机制
  • 批准号:
    8494640
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:
Activation and Regulation Mechanisms of cGMP-dependent Protein Kinase I and II
cGMP依赖性蛋白激酶I和II的激活和调节机制
  • 批准号:
    9506783
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:
Targeting mechanisms of cGMP dependent protein kinases by peptide arrays and crys
肽阵列和crys的cGMP依赖性蛋白激酶靶向机制
  • 批准号:
    7777237
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:
Activation and Regulation Mechanisms of cGMP-dependent Protein Kinase I and II
cGMP依赖性蛋白激酶I和II的激活和调节机制
  • 批准号:
    9102231
  • 财政年份:
    2010
  • 资助金额:
    $ 30.21万
  • 项目类别:

相似国自然基金

基于亲和导向-邻近反应的复杂体系天然蛋白固定新方法及色谱评价
  • 批准号:
    22374116
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
基于亲和色谱策略筛选和挖掘磷酸酶PP2A新型调节剂
  • 批准号:
    22377149
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目
基于仿生亲和色谱-质谱策略的肺结核患者血清抗体谱研究
  • 批准号:
    82160027
  • 批准年份:
    2021
  • 资助金额:
    34 万元
  • 项目类别:
    地区科学基金项目
基于亲和色谱靶点“钩钓”策略研究补肾活血方抗AGEs诱导神经损伤的作用机制
  • 批准号:
    82104621
  • 批准年份:
    2021
  • 资助金额:
    24.00 万元
  • 项目类别:
    青年科学基金项目
固定化单构象态受体亲和色谱的建立及止喘灵方平喘功效物质研究
  • 批准号:
    82174088
  • 批准年份:
    2021
  • 资助金额:
    55.00 万元
  • 项目类别:
    面上项目

相似海外基金

Novel approach to identify RNA-bound small molecules in vivo
体内鉴定 RNA 结合小分子的新方法
  • 批准号:
    10646626
  • 财政年份:
    2023
  • 资助金额:
    $ 30.21万
  • 项目类别:
DeADP-ribosylation of host targets mediated by a bacterial effector
由细菌效应子介导的宿主靶标的 DeADP-核糖基化
  • 批准号:
    10667971
  • 财政年份:
    2023
  • 资助金额:
    $ 30.21万
  • 项目类别:
Oxidative Lipidomics in Pediatric Traumatic Brain Injury
氧化脂质组学在小儿创伤性脑损伤中的应用
  • 批准号:
    10844023
  • 财政年份:
    2023
  • 资助金额:
    $ 30.21万
  • 项目类别:
Activity-Dependent Regulation of CaMKII and Synaptic Plasticity
CaMKII 和突触可塑性的活动依赖性调节
  • 批准号:
    10817516
  • 财政年份:
    2023
  • 资助金额:
    $ 30.21万
  • 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
  • 批准号:
    10760236
  • 财政年份:
    2023
  • 资助金额:
    $ 30.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了